The Ensign Group (NASDAQ:ENSG) Raised to Buy at Wall Street Zen
by Michael Walen · The Markets DailyThe Ensign Group (NASDAQ:ENSG – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Sunday, Wall Street Zen reports.
Several other research firms have also issued reports on ENSG. Royal Bank Of Canada restated an “outperform” rating and issued a $228.00 price target on shares of The Ensign Group in a research report on Tuesday, July 28th. Truist Financial upped their price objective on shares of The Ensign Group from $202.00 to $207.00 and gave the company a “hold” rating in a research report on Thursday, July 30th. Finally, Weiss Ratings upgraded shares of The Ensign Group from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Four equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, The Ensign Group currently has a consensus rating of “Moderate Buy” and a consensus target price of $216.25.
Read Our Latest Stock Report on The Ensign Group
The Ensign Group Stock Up 0.8%
ENSG stock opened at $176.92 on Friday. The firm has a market cap of $10.31 billion, a PE ratio of 27.73, a PEG ratio of 1.66 and a beta of 0.66. The Ensign Group has a 1 year low of $141.58 and a 1 year high of $218.00. The company has a fifty day simple moving average of $174.89 and a 200 day simple moving average of $181.50. The company has a current ratio of 1.21, a quick ratio of 1.21 and a debt-to-equity ratio of 0.06.
The Ensign Group (NASDAQ:ENSG – Get Free Report) last announced its earnings results on Monday, July 27th. The company reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.80 by $0.12. The firm had revenue of $1.44 billion during the quarter, compared to analysts’ expectations of $1.44 billion. The Ensign Group had a return on equity of 16.75% and a net margin of 6.90%. The company’s revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.59 earnings per share. Sell-side analysts anticipate that The Ensign Group will post 7.04 EPS for the current fiscal year.
Institutional Trading of The Ensign Group
Hedge funds and other institutional investors have recently made changes to their positions in the business. Peterson Wealth Services raised its position in shares of The Ensign Group by 8.9% during the third quarter. Peterson Wealth Services now owns 7,981 shares of the company’s stock worth $1,373,000 after acquiring an additional 650 shares during the last quarter. Apollon Wealth Management LLC boosted its holdings in The Ensign Group by 22.9% in the third quarter. Apollon Wealth Management LLC now owns 6,986 shares of the company’s stock valued at $1,202,000 after acquiring an additional 1,300 shares during the last quarter. Citizens Financial Group Inc. RI bought a new position in The Ensign Group in the third quarter valued at about $254,000. Evergreen Capital Management LLC boosted its holdings in The Ensign Group by 13.3% in the third quarter. Evergreen Capital Management LLC now owns 3,735 shares of the company’s stock valued at $643,000 after acquiring an additional 437 shares during the last quarter. Finally, Wedbush Securities Inc. acquired a new stake in The Ensign Group in the third quarter worth about $207,000. 96.12% of the stock is currently owned by institutional investors and hedge funds.
Key Headlines Impacting The Ensign Group
Here are the key news stories impacting The Ensign Group this week:
- Positive Sentiment: Wall Street Zen upgraded The Ensign Group to “Buy,” providing a favorable analyst signal ahead of earnings. The Ensign Group Stock Bumped Up to Buy by Wall Street Zen
- Neutral Sentiment: The company is expected to report quarterly results on October 27. Earnings could become the next major catalyst, particularly as investors assess operating performance and forward guidance. The Ensign Group to Report Earnings Tomorrow
- Neutral Sentiment: A short-interest update reported zero shares sold short and a zero-day days-to-cover ratio as of October 26. That reading conflicts with the headline describing a significant increase, so the data may be incomplete or misstated and offers little reliable trading insight.
- Negative Sentiment: Multiple law firms publicized an existing securities class action against The Ensign Group and certain officers. The case covers investors who purchased securities from February 10, 2022, through June 18, 2026, and alleges the company failed to disclose material adverse information, including claims involving neglect and regulatory representations. The allegations have not been proven. Bronstein Gewirtz Grossman Class Action Announcement Lead Plaintiff Deadline Alert
- Negative Sentiment: Investors have until December 7, 2026, to seek appointment as lead plaintiff. Continued legal-firm promotion may increase attention on potential financial, reputational, and litigation risks, potentially weighing on ENSG if the claims gain traction. Rosen Law Firm Ensign Group Deadline Notice
The Ensign Group Company Profile
The Ensign Group, Inc is a healthcare services company that provides skilled nursing, post-acute care and rehabilitation services. Its facilities serve patients recovering from illness, injury or surgery, as well as individuals requiring long-term nursing care and support with daily living.
Through its operating subsidiaries, Ensign also provides assisted living and other senior care services. Its portfolio includes skilled nursing facilities, senior living communities and related healthcare operations, with services such as physical, occupational and speech therapy, medically complex care and rehabilitation.
Founded in 1999 and headquartered in San Juan Capistrano, California, The Ensign Group operates healthcare facilities across multiple U.S.
Featured Articles
- Five stocks we like better than The Ensign Group
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants